What to Expect When Tilray Reports After the Close

By Chris Lange Updated Mar 13, 10:25PM EDT · Published Nov 12, 12:40PM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

What to Expect When Tilray Reports After the Close — © serdjophoto / Getty Images

Tilray Inc. (NASDAQ: TLRY) is scheduled to release its third-quarter financial results after the markets close on Tuesday. The consensus estimates are calling for a net loss of $0.29 per share and $49.41 million in revenue. The same period of last year reportedly had a net loss of $0.20 per share and $10.05 million in revenue.

In the second quarter, revenues increased 371% year over year, driven by the Manitoba Harvest acquisition, the legalization of the Canadian adult-use market, and growth in international medical markets, particularly in Europe.

At the same time, total kilogram equivalents sold more than tripled to 5,588 kilograms from 1,514 kilograms in the prior-year period.

Also, the average net selling price per gram decreased to $4.61 compared to $6.38 in the prior-year period. The average net selling price excluding excise taxes was $3.92 per gram for the second quarter of 2019. The decrease was due to a reduced mix of higher-priced extract products and a greater mix of adult-use revenue, which are at lower prices per gram compared to other channels.

Excluding Tuesday’s move, Tilray had underperformed the broad markets, with the stock down about 69% year to date. In the past 52 weeks, the stock was down about 81.5%.

[nativounit]

A few analysts weighed in on Tilray ahead of the report:

Cantor Fitzgerald has a Neutral rating and a $20 price target.
Jefferies has a Hold rating with a $25 target price.
Piper Jaffray has an Overweight rating and a $31 target.
MKM Partners rates it as Neutral with a $34 price target.
Cowen’s Buy rating comes with a $60 target price.

Shares of Tilray traded down about 4% to $20.90 on Tuesday, in a 52-week range of $20.20 to $120.40. The consensus price target is $37.00.

[recirclink id=591894]
[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.